BRCA1 and cancer: Several PARPi (e.g., Olaparib, Rucaparib, Talazoparib, and Niraparib) have been approved as monotherapy for either breast, ovarian or both cancers associated with BRCA1/2 germline mutations or HR-deficiency [17].